Con is a senior healthcare communicator with over 18 years’ agency experience in leading corporate reputation, brand and issues readiness programmes for some of the biggest names in global medicine.
From 2011 to 2014 he led global communication strategy for Bayer and its flagship pharmaceutical Xarelto®from its phase III program to launch in the product’s first four antithrombotic indications, alongside the development of a comprehensive issues readiness protocol for management of potential safety and AE challenges. He also acted as the global-to-local communications link between Bayer’s German HQ and its UK affiliate business.
Across 2015-2016, Con led major workstreams for the EU pharmaceutical trade body EFPIA on outcomes-driven sustainable healthcare and defending the European pharma industry’s position on the price of medicines. Further healthcare comms experience includes worldwide virology communication strategy for AbbVie, global brand planning for Pfizer’s neuropathic pain brand Lyrica®, and extensive work with Shire for several years delivering worldwide data communication, KOL and brand strategy for its orphan and rare disease portfolio. Con has created reputation-boosting programmes for leading academic institutions including Harvard Medical School and the premier Swiss university EPFL, bringing their respective gene therapy, neuroscience and neuroengineering research breakthroughs to a wide global audience of media, investors and commercialisation partners.
He is a 2019 Communiqué Healthcare Awards Judge and a guest lecturer on healthcare communications at Imperial College London.
Strictly Necessary Cookies
Strictly Necessary Cookies are enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
3rd Party Cookies
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
This website uses Lead Forensics to track website usage for businesses predominantly through IP addresses that are registered to a business as static. We a use persistent cookie for those visitors that is used to further improve the insights we receive from data collected from those business users.
Please enable Strictly Necessary Cookies first so that we can save your preferences!